Position in ARVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,459,152
-$915,142 QoQ
Shares Held
175,590
-21.6% QoQ
Ownership
0.269%
of shares outstanding
% of Portfolio
1.46%
of 13F equity value
Holder Rank
#45
of 201 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Rangeley Capital, LLC holds $27,388,910 across 46 Biotechnology names. ARVN ranks #8 (5.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRTA |
Prothena Corp Public Ltd Co
|
417,270 | $4,085,073 | |
| 2 | ABUS |
Arbutus Biopharma Corp
|
500,000 | $2,400,000 | |
| 3 | ABVX |
Abivax S.A.
|
13,000 | $1,732,380 | |
| 4 | TBPH |
Theravance Biopharma, Inc.
|
99,500 | $1,691,500 | |
| 5 | RLYB |
Rallybio Corp
|
104,850 | $1,677,600 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
33,700 | $1,629,336 | |
| 7 | JANX |
Janux Therapeutics, Inc.
|
97,978 | $1,504,942 | |
| 8 | ARVN |
Arvinas, Inc.
This page
|
175,590 | $1,459,152 |
All Filings in ARVN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,459,152 | 175,590 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,374,294 | 223,990 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,694,188 | 395,800 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $5,924,808 | 695,400 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $5,113,728 | 694,800 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,811,860 | 543,000 | Shares | Sole | 2025-05-14 | |
| No filing history on record for this holder in this stock. | ||||||